Fig. 2: Day 29 RSV nAb (IU/mL) and IgG bAb (AU/mL) by RSV-LRTD-2+ case status and by vaccine and placebo in the Day 29 case-cohort set.
From: Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial
a RSV-A nAb. b RSV-B nAb. c RSV preF IgG bAb. d RSV postF IgG bAb. The violin-box plot is composed of an interior box plot and rotated probability density plots (estimated by a default Gaussian kernel density estimator) of the antibody marker data on each side. In the box plot, the middle line and the lower and upper horizonal edges represent the 50th, 25th, and 75th percentile of antibody titers or concentrations, and the vertical whiskers represent the distance from the 25th (or 75th) percentiles of antibody titers or concentrations and the minimum (or maximum) antibody titers or concentrations within the 25th (or 75th) percentile of antibody level minus (or plus) 1.5 times the interquartile range. The GMT or GMC level and the corresponding 95% confidence interval are adjusted by the IPS-weight. ARD acute respiratory disease, bAb binding antibody, GMC geometric mean concentration, GMT geometric mean titer, IgG immunoglobulin G, IPS inverse probability of sampling, LLOQ lower limit of quantification, LRTD lower respiratory tract disease, nAb neutralizing antibody, postF postfusion, preF prefusion, RSV respiratory syncytial virus, ULOQ upper limit of quantification.
